Delivra Health Brands Inc.
Driving Revenue Growth via New Products & a Bolstered Marketing Budget
Published: 2/29/2024
Author: Sid Rajeev, B.Tech, CFA, MBA
Sector: Healthcare | Industry: Drug Manufacturers-Specialty & Generic
| Metrics | Value |
|---|---|
| Current Price | US $0.04 |
| Fair Value | US $0.07 |
| Risk | 3 |
| 52 Week Range | US $0.01-0.04 |
| Shares O/S (M) | 313 |
| Market Cap. (M) | US $11 |
| Current Yield (%) | n/a |
| P/E (forward) | n/a |
| P/B | 2.9 |
Already a subscriber?
Want to know the fair value of the stock?
Subscribe for free to get exclusive insights and data.
Report Highlights
Highlights
DHB is up 75% since our previous report in December 2023. Check out our recent interview with DHB's CEO for in-depth insights into the company's products, marketing strategies, competitive landscape, and upcoming plans.
Q2-FY2024 (ended December 2023) revenue was down 14% YoY, but gross profit was up 12% YoY, driven by cost reductions stemming from improved terms with distributors. H1-FY2024 revenue was up 39% YoY, and gross profit was up 65% YoY.
As Q1 revenue was up 112% YoY, the decline in Q2 may appear concerning. However, it is important to note that DHB’s revenue fluctuates quarterly due to the timing of shipment of sales orders
